The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of lorlatinib in patients (pts) with ALK-positive (ALK+) lung cancer with brain-only progression.
 
Ibiayi Dagogo-Jack
Honoraria - Foundation Medicine
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - Array BioPharma (Inst); Guardant Health (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Geoffrey R. Oxnard
Honoraria - Foundation Medicine; Guardant Health; Sysmex
Consulting or Advisory Role - Abbvie; AstraZeneca; DropWorks; GRAIL; Illumina; Inivata; Janssen; LOXO; Merck; Merck; Sysmex; Takeda
Patents, Royalties, Other Intellectual Property - DFCI has a patent pending titled "Non-invasive blood-based monitoring of genomic alterations in cancer", on which I am a co-author. (Inst)
 
Jessica Fink
No Relationships to Disclose
 
Gianluca Diubaldi
No Relationships to Disclose
 
Caitlyn Helms
No Relationships to Disclose
 
Justin F. Gainor
Employment - Ironwood Pharmaceuticals (I)
Stock and Other Ownership Interests - Ironwood Pharmaceuticals (I)
Honoraria - ARIAD; Incyte; Merck; Novartis; Pfizer; Takeda
Consulting or Advisory Role - Agios; Amgen; Array BioPharma; Blueprint Medicines; Bristol-Myers Squibb; Genentech; Gilead Sciences; Jounce Therapeutics; Lilly; Loxo; Merck; Moderna Therapeutics; Oncorus; Regeneron; Takeda; Theravance
Research Funding - Adaptimmune (Inst); Alexo Therapeutics (Inst); ARIAD; Array BioPharma (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Genentech; Jounce Therapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Tesaro (Inst)
 
Michael S. Rabin
No Relationships to Disclose
 
Rebecca Suk Heist
Honoraria - Chugai/Roche
Consulting or Advisory Role - Apollomics; Boehringer Ingelheim; Novartis; Tarveda Therapeutics
Research Funding - Abbvie (Inst); Agios (Inst); Celgene (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); Exelixis (Inst); Exelixis (Inst); Incyte (Inst); Lilly (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Peregrine Pharmaceuticals (Inst); Pfizer (Inst); Pfizer (Inst); Roche (Inst); Turning Point Therapeutics (Inst)
 
Jessica Jiyeong Lin
Honoraria - OncLive; Pfizer
Consulting or Advisory Role - C4 Therapeutics; Genentech; Nuvalent, Inc.
Research Funding - Hengrui Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Jennifer Ackil
No Relationships to Disclose
 
Alona Muzikansky
Consulting or Advisory Role - Sofregen
 
Alice Tsang Shaw
Employment - Novartis Institutes for BioMedical Research
Leadership - Syros Pharmaceuticals
Stock and Other Ownership Interests - Novartis Institutes for BioMedical Research
Honoraria - Foundation medicine; Guardant Health; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - Achilles Therapeutics; ARIAD; Bayer; Blueprint Medicines; Chugai Pharma; Daiichi Sankyo; EMD Serono; Genentech; Ignyta; KSQ Therapeutics; Loxo; Natera; Novartis; Pfizer; Roche; Taiho Pharmaceutical; Takeda
Research Funding - ARIAD (Inst); Daiichi Sankyo (Inst); Ignyta (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); TP Therapeutics (Inst)